chr2-151619514-C-G

Variant summary

Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_001164508.2(NEB):​c.10809G>C​(p.Trp3603Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.31 in 1,613,274 control chromosomes in the GnomAD database, including 80,452 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.26 ( 5713 hom., cov: 32)
Exomes 𝑓: 0.32 ( 74739 hom. )

Consequence

NEB
NM_001164508.2 missense

Scores

5
6
7

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:15

Conservation

PhyloP100: 3.22
Variant links:
Genes affected
NEB (HGNC:7720): (nebulin) This gene encodes nebulin, a giant protein component of the cytoskeletal matrix that coexists with the thick and thin filaments within the sarcomeres of skeletal muscle. In most vertebrates, nebulin accounts for 3 to 4% of the total myofibrillar protein. The encoded protein contains approximately 30-amino acid long modules that can be classified into 7 types and other repeated modules. Protein isoform sizes vary from 600 to 800 kD due to alternative splicing that is tissue-, species-,and developmental stage-specific. Of the 183 exons in the nebulin gene, at least 43 are alternatively spliced, although exons 143 and 144 are not found in the same transcript. Of the several thousand transcript variants predicted for nebulin, the RefSeq Project has decided to create three representative RefSeq records. Mutations in this gene are associated with recessive nemaline myopathy. [provided by RefSeq, Sep 2009]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0016649961).
BP6
Variant 2-151619514-C-G is Benign according to our data. Variant chr2-151619514-C-G is described in ClinVar as [Benign]. Clinvar id is 95102.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-151619514-C-G is described in Lovd as [Benign]. Variant chr2-151619514-C-G is described in Lovd as [Likely_benign].
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.327 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
NEBNM_001164507.2 linkc.10809G>C p.Trp3603Cys missense_variant Exon 73 of 182 ENST00000427231.7 NP_001157979.2
NEBNM_001164508.2 linkc.10809G>C p.Trp3603Cys missense_variant Exon 73 of 182 ENST00000397345.8 NP_001157980.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
NEBENST00000397345.8 linkc.10809G>C p.Trp3603Cys missense_variant Exon 73 of 182 5 NM_001164508.2 ENSP00000380505.3 P20929-2
NEBENST00000427231.7 linkc.10809G>C p.Trp3603Cys missense_variant Exon 73 of 182 5 NM_001164507.2 ENSP00000416578.2 P20929-3
NEBENST00000409198.5 linkc.10080G>C p.Trp3360Cys missense_variant Exon 70 of 150 5 ENSP00000386259.1 P20929-4

Frequencies

GnomAD3 genomes
AF:
0.262
AC:
39871
AN:
151940
Hom.:
5709
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.140
Gnomad AMI
AF:
0.149
Gnomad AMR
AF:
0.264
Gnomad ASJ
AF:
0.225
Gnomad EAS
AF:
0.248
Gnomad SAS
AF:
0.216
Gnomad FIN
AF:
0.354
Gnomad MID
AF:
0.295
Gnomad NFE
AF:
0.330
Gnomad OTH
AF:
0.261
GnomAD3 exomes
AF:
0.292
AC:
72637
AN:
248552
Hom.:
11133
AF XY:
0.290
AC XY:
39028
AN XY:
134792
show subpopulations
Gnomad AFR exome
AF:
0.139
Gnomad AMR exome
AF:
0.319
Gnomad ASJ exome
AF:
0.236
Gnomad EAS exome
AF:
0.263
Gnomad SAS exome
AF:
0.215
Gnomad FIN exome
AF:
0.341
Gnomad NFE exome
AF:
0.326
Gnomad OTH exome
AF:
0.299
GnomAD4 exome
AF:
0.315
AC:
460833
AN:
1461216
Hom.:
74739
Cov.:
40
AF XY:
0.312
AC XY:
226923
AN XY:
726800
show subpopulations
Gnomad4 AFR exome
AF:
0.138
Gnomad4 AMR exome
AF:
0.313
Gnomad4 ASJ exome
AF:
0.232
Gnomad4 EAS exome
AF:
0.258
Gnomad4 SAS exome
AF:
0.210
Gnomad4 FIN exome
AF:
0.338
Gnomad4 NFE exome
AF:
0.333
Gnomad4 OTH exome
AF:
0.295
GnomAD4 genome
AF:
0.262
AC:
39883
AN:
152058
Hom.:
5713
Cov.:
32
AF XY:
0.263
AC XY:
19565
AN XY:
74308
show subpopulations
Gnomad4 AFR
AF:
0.139
Gnomad4 AMR
AF:
0.265
Gnomad4 ASJ
AF:
0.225
Gnomad4 EAS
AF:
0.248
Gnomad4 SAS
AF:
0.217
Gnomad4 FIN
AF:
0.354
Gnomad4 NFE
AF:
0.330
Gnomad4 OTH
AF:
0.258
Alfa
AF:
0.312
Hom.:
5653
Bravo
AF:
0.253
TwinsUK
AF:
0.340
AC:
1262
ALSPAC
AF:
0.338
AC:
1301
ESP6500AA
AF:
0.139
AC:
564
ESP6500EA
AF:
0.331
AC:
2784
ExAC
AF:
0.288
AC:
34864
Asia WGS
AF:
0.233
AC:
811
AN:
3478
EpiCase
AF:
0.313
EpiControl
AF:
0.312

ClinVar

Significance: Benign
Submissions summary: Benign:15
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:7
-
Genetic Services Laboratory, University of Chicago
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. -

May 07, 2014
Eurofins Ntd Llc (ga)
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Nov 26, 2014
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

p.Trp3603Cys in exon 73 of NEB: This variant is not expected to have clinical si gnificance because it has been identified in 33% (2784/8400) of European America n chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.ed u/EVS/; dbSNP rs10172023). -

-
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jan 05, 2016
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Nemaline myopathy 2 Benign:5
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

May 28, 2019
Mendelics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Sep 16, 2020
Natera, Inc.
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jul 10, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

Apr 24, 2017
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: The NEB c.10809G>C (p.Trp3603Cys) variant involves the alteration of a non-conserved nucleotide and 3/3 in silico tools (SNPsandGo and Mutation Taster not captured here due to low reliability index and p-value, respectively) predict a damaging outcome. This variant was found in 34849/120540 control chromosomes (5272 homozygotes) at a frequency of 0.2891074, which is approximately 82 times the estimated maximal expected allele frequency of a pathogenic NEB variant (0.0035355), suggesting this variant is likely a benign polymorphism. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely benign/benign. Therefore, the variant of interest has been classified as Benign. -

Arthrogryposis multiplex congenita 6 Benign:1
Jul 10, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.94
BayesDel_addAF
Benign
-0.32
T
BayesDel_noAF
Benign
-0.090
CADD
Uncertain
26
DANN
Uncertain
0.99
DEOGEN2
Benign
0.22
.;.;T;.;D;.;.
Eigen
Uncertain
0.66
Eigen_PC
Uncertain
0.58
FATHMM_MKL
Benign
0.065
N
LIST_S2
Pathogenic
0.98
D;D;D;D;D;.;.
MetaRNN
Benign
0.0017
T;T;T;T;T;T;T
MetaSVM
Benign
-1.1
T
MutationAssessor
Pathogenic
3.3
M;.;.;.;M;.;.
PrimateAI
Uncertain
0.66
T
PROVEAN
Pathogenic
-5.2
D;D;.;D;D;.;.
REVEL
Uncertain
0.30
Sift
Uncertain
0.0060
D;D;.;D;D;.;.
Sift4G
Pathogenic
0.0
D;D;D;D;D;D;D
Polyphen
1.0
.;.;.;.;D;.;.
Vest4
0.68
MutPred
0.58
Loss of catalytic residue at W3360 (P = 0.0794);.;.;.;Loss of catalytic residue at W3360 (P = 0.0794);.;.;
MPC
0.42
ClinPred
0.016
T
GERP RS
5.6
Varity_R
0.59
gMVP
0.62

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs10172023; hg19: chr2-152476028; COSMIC: COSV51216946; COSMIC: COSV51216946; API